History of GW Pharmaceuticals
- Founded in 1998 by doctors Geoffrey Guy and Brian Whittle.
- Obtained cultivation license from the UK Home Office and MHRA in 1998.
- Entered a contract with Hortapharm B.V. in 1998.
- Listed on the Alternative Investment Market in 2001.
- Dual-listed on NASDAQ and AIM in May 2013.
Products Developed by GW Pharmaceuticals
- Sativex (Nabiximols) approved in the UK in 2010 for MS patients.
- Partnership with Bayer for Sativex distribution in the UK in 2020.
- Estimated annual production of 100 tons of medicinal cannabis.
- Epidiolex (cannabidiol oral solution) approved by FDA in June 2018.
Sativex by GW Pharmaceuticals
- Administered as a mouth spray.
- Approved in the UK for multiple sclerosis patients.
- Extracted with ethanol and carbon dioxide.
- Annual production estimated at 100 tons.
- Partnership with Bayer for UK distribution.
Epidiolex by GW Pharmaceuticals
- Phase 3 clinical trials initiated in 2015 for Dravet syndrome and Lennox–Gastaut syndrome.
- Received FDA Fast Track Development Program designation in 2015.
- FDA approved Epidiolex in June 2018.
- European EMA approval under the brand name Epidyolex in September 2019.
- Used for newborns with epilepsy.
Related Concepts and Products
- Cannabis portal.
- Dronabinol.
- Marinol.
- Nabilone.
- Medical use of cannabis.
GW Pharmaceuticals Data Sources
| Reference | URL |
|---|---|
| Glossary | https:/glossary/gw-pharmaceuticals |
| Wikipedia | https://en.wikipedia.org/wiki/GW_Pharmaceuticals |
| Wikidata | https://www.wikidata.org/wiki/Q3093459 |
| Knowledge Graph | https://www.google.com/search?kgmid=/m/0k967d3 |
| DBPedia | http://dbpedia.org/resource/GW_Pharmaceuticals |
| Product Ontology | http://www.productontology.org/id/GW_Pharmaceuticals |